rapporto sulle attività - FPRC - Fondazione Piemontese per la ...
rapporto sulle attività - FPRC - Fondazione Piemontese per la ...
rapporto sulle attività - FPRC - Fondazione Piemontese per la ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Unità di Oncologia Medica, <strong>per</strong>sonale<br />
Ricerca clinica e <strong>attività</strong> cliniche<br />
Aglietta Massimo, M.D. Fizzotti Marco, M.D. Piacibello Wanda, M.D. *<br />
Aliberti, Sandra M.D. Gammaitoni Loretta, Dr. * Pignochino Ymera, Ph.D *<br />
Allione Paolo, M.D. Garetto Lucia, M.D. Redana Stefania, M.D.<br />
Bucci Sabrina, M.D. Grignani Giovanni Enrico, M.D. Rota Sca<strong>la</strong>brini Delia, M.D.<br />
Caione Luisa, Dr. * Gunetti Monica, Ph.D * Sangiolo Dario, PhD *<br />
Cammarata Cristina, Dr. * Jordaney Noe<strong>la</strong>, Dr. * S<strong>per</strong>ti Elisa, M.D.<br />
Capaldi Antonio, M.D. Leone Francesco, M.D. Tesio Me<strong>la</strong>nia, Ph.D *<br />
Carnevale-Schianca Fabrizio, M.D. Leuci Valeria, Ph.D * Va<strong>la</strong>brega Giorgio, M.D<br />
Cavalloni Giuliana, Ph.D. * Migliardi Giorgia, Ph.D * Vormo<strong>la</strong> Roberto, M.D.<br />
Faggiuolo Roberto, M.D. Montemurro Filippo, M.D.<br />
Ferraris Renato, M.D. Ortega Cinzia, M.D.<br />
Unità di Oncologia Medica, pubblicazioni 2005<br />
• Montemurro F, Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast<br />
cancer. Clin Breast Cancer 6: 77-80, 2005. IF: NA<br />
• Montemurro F. Target achieved. Ex<strong>per</strong>t Opin Pharmacother 6: 1047-1048, 2005. IF: NA<br />
• Montemurro F. Adjuvant therapy: a new era. Tumori 91: 13-18, 2005. IF: .631<br />
• Berger M, Frairia R, Piacibello W, Sanavio F, Palmero A, Venturi C, Pignochino Y, Berta L, Madon E, Aglietta M, Fagioli<br />
F. Feasibility of cord blood stem cell manipu<strong>la</strong>tion with high-energy shock waves: An in vitro and in vivo study. Exp<br />
Hematol. 33:1371-87, 2005.<br />
• Byk T, Kahn J, Kollet O, Petit I, Samira S, Shivtiel S, Ben-Hur H, Peled A, Piacibello W, Lapidot T. Cycling G1<br />
CD34+/CD38+ cells potentiate the motility and engraftment of quiescent G0 CD34+/CD38-/low severe combined<br />
immunodeficiency repopu<strong>la</strong>ting cells. Stem Cells 23: 561-574, 2005. IF: 5.500<br />
• Cignetti A, Val<strong>la</strong>rio A, Follenzi A, Circosta P, Capaldi A, Gottardi D, Naldini L, Caligaris-Cappio F. Lentiviral transduction<br />
of primary myeloma cells with CD80 and CD154 generates antimyeloma effector T cells. Hum Gene Ther 16: 445-<br />
456, 2005. IF: 4.857<br />
• Montemurro F, Martincich L, De Rosa G, Cirillo S, Marra V, Biglia N, Gatti M, Sismondi P, Aglietta M, Regge D. Dynamic<br />
contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol 15:<br />
1224-1233, 2005. IF: 2.364<br />
• Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mito<strong>la</strong> S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W,<br />
Aglietta M. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor<br />
progression. Clin Cancer Res 11: 490-497, 2005. IF: 5.623<br />
• Risio M, Casorzo L, Redana S, Montemurro F. HER2 gene-amplified breast cancers with monosomy of chromosome<br />
17 are poorly responsive to trastuzumab-based treatment; Oncol Rep 13: 305-309, 2005. IF: 1.356<br />
• Montemurro F, Faggiuolo R, Redana S, Donadio M, Minischetti M, Durando A, Vietti-Ramus G, Buosi R, Aglietta M.<br />
Continuation of trastuzumab beyond disease progression. J Clin Oncol 23: 2866-2868, 2005. IF: 9.835<br />
• Busso<strong>la</strong>ti G, Montemurro F, Righi L, Donadio M, Aglietta M, Sapino A. A modified Trastuzumab antibody for the<br />
immunohistochemical detection of HER-2 overexpression in breast cancer. Br J Cancer 92: 1261-1267, 2005. IF: 3.742<br />
• Grignani G, Perissinotto E, Cavalloni G, Carnevale Schianca F, Aglietta M. Clinical use of AMD3100 to mobilize CD34+<br />
cells in patients affected by non-Hodgkin’s lymphoma or multiple myeloma. J Clin Oncol 23: 3871-3872, 2005. IF:<br />
9.835<br />
• Montemurro F, Redana S, Va<strong>la</strong>brega G, Aglietta M. Controversies in breast cancer: adjuvant and neoadjuvant thera-<br />
py. Ex<strong>per</strong>t Opin Pharmacother 6: 1055-1072, 2005. IF: NA<br />
* Personale del Laboratorio di Ricerca di Oncologia Medica<br />
65
Change language